NEW YORK (GenomeWeb) – Quanterix reported after the close of the market on Wednesday that its fourth quarter revenues fell 1 percent year-over-year.

The company posted Q4 revenues of $6.6 million, down from $6.7 million in Q4 2016 and below the consensus Wall Street estimate of $6.7 million.

Quanterix noted that the Q4 2016 figure included $1.8 million of non-recurring license revenue and that Q4 2017 revenues were up 35 percent year-over-year once that non-recurring figure was excluded.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
14

In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.